Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201

Therapy in BRCA-Negative Ovarian Cancer Patients -

BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.

"We believe BSI-201 holds great promise as a targeted therapy in this difficult-to-treat type of ovarian cancer," said Carol Aghajanian, M.D., co- principal investigator and chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center. "BRCA-negative patients are at higher risk of breast and ovarian cancer because BRCA plays a key role in repairing DNA errors that lead to tumor formation."

Ovarian cancer strikes more than 21,000 women a year in the United States and is one of the most common causes of cancer death in women, killing more than 15,000 annually in the United States. Patients with the hereditable BRCA- negative form of the disease account for about 15 percent of the patient population. Women with defective BRCA genes are also at considerably higher risk of breast cancer.

"We have identified a number of important types of cancer where PARP plays a crucial role in tumor growth, and we believe that BRCA-negative ovarian cancer represents another excellent target for BSI-201," said Barry Sherman, M.D., BiPar's Executive Vice President of Development. "We will soon have patients enrolled in four separ
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2009)..., AMSTERDAM, The Netherlands, June 30 /PRNewsw...on the Decision-Making Process With,Respect to In...nomic analysis presented today at this year,s,Eur... (ESHRE) congress showed,that, within the paramet...rtilisation (IVF) treatment MENOPUR (highly-purifi...
(Date:6/29/2009)..., SOUTHAMPTON, England, June 29 /PRNewswire/ -... company developing novel, small molecule drugs,t...nces positive results from,a Phase IIa clinical t...,nocturia. The trial showed that oral VA106483 wa...ined anti-diuretic effect in patients, as determin...
(Date:6/26/2009)..., BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall...NY ) has just been made aware of data associated w...stries. The results of these data clearly show tha... a possible causal relationship between Lantus(R) ...currence of malignancies, as the authors of the st...
(Date:6/25/2009)..., NEW YORK, June 25 As ...kinson,s Research has already funded over $1 milli...on,s therapeutic development through its groundbre... include investigations of the safety and efficacy...at Parkinson,s; characterization of a tenuous link...
Breaking Medicine Technology:New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 2MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 3Two is not company as far as fish are concerned 9044 1The National Council on Aging and CVS pharmacy Educate Pennsylvania Seniors on Medication Management and How to Save Money on Prescription Drugs 50279 1The National Council on Aging and CVS pharmacy Educate Pennsylvania Seniors on Medication Management and How to Save Money on Prescription Drugs 50279 2The National Council on Aging and CVS pharmacy Educate Pennsylvania Seniors on Medication Management and How to Save Money on Prescription Drugs 50279 3The National Council on Aging and CVS pharmacy Educate Pennsylvania Seniors on Medication Management and How to Save Money on Prescription Drugs 50279 4DuoCort 3A New chronotherapy for adrenal insufficiency 9039 1DuoCort 3A New chronotherapy for adrenal insufficiency 9039 2DuoCort 3A New chronotherapy for adrenal insufficiency 9039 3Health Robotics Announces i v STATION 28TM 29 Contract With Grifols in Spain Portugal and South America 50272 1Health Robotics Announces i v STATION 28TM 29 Contract With Grifols in Spain Portugal and South America 50272 2Health Robotics Announces i v STATION 28TM 29 Contract With Grifols in Spain Portugal and South America 50272 3
...2007 - Geron,Corporation (Nasdaq:GERN) today refer...rase and telomeres in cancer at this year,s,Americ...eeting in,Los Angeles. There were approximately 80...reflecting the growing body of evidence,supporting...r,target for drug and vaccine development. Geron h...
...- Reata,Pharmaceuticals, Inc. today announced the ...ny,s Synthetic Triterpenoid programs in,the May 20...s,Cancer.", The article, "Triterpenoids and rexino...nd treatment of cancer," by researchers,and Reata ...l,School Karen T. Liby, Mark M. Yore and Michael B...
Other Medicine Technology:Telomerase Presentations at the AACR 2007 Annual Meeting 2Telomerase Presentations at the AACR 2007 Annual Meeting 3Telomerase Presentations at the AACR 2007 Annual Meeting 4Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4
(Date:7/2/2009)...dy explores weight problems faced by youngsters wi...lthDay News) -- Children with type 1 diabetes are ...e disease, increasing their risk of serious health...is from a major study that explored the weight pro...s, a less common form of the disease that usually ...
(Date:7/2/2009)...everal statistical and biological issues need to b...cation for early detection of cancer, according to...nal of the National Cancer Institute . , The bio...eening tests includes the identification of promis...tial and definitive evaluation of biomarkers for c...
(Date:7/2/2009)...rostate cancer patients who receive brachytherapy ...er are unlikely to have a recurrence at 10 years, ...nternational Journal of Radiation Oncology*Biology...ciety for Radiation Oncology (ASTRO)., Brachyther...just next to a tumor either permanently or tempora...
(Date:7/2/2009)... evaluation urged for youngsters taking common ant... 2 (HealthDay News) -- A common antibacterial trea...hearing loss, finds a new study. , Researchers ... patients treated over a 13-year period at Childre...nt) of them suffered from sensorineural hearing lo...
Breaking Medicine News(10 mins):Health News:Kids With Type 1 Diabetes Often Overweight 2
...nment vets are probing an outbreak of bird flu in ...hundreds of turkeys. Reports of an ‘unexplained’ i...estigate. Confirmation has been received from The...ural Affairs about a bird-flu outbreak. This is th...
...ide, a little-known lipid plays a crucial role in ...eings, researchers have found. It seems to help in...heir respective positions. They found that in the...ps stem cells line up to form the primitive ectode...
...dy by Penn State College of Medicine finds that na...disease. A low dose of this drug is often used to ...ction. Crohn’s disease is a chronic inflammatory ... an estimated 500,000 Americans. The study results...
...ding to a study published in the February 1st issu...e common, and often more frequent than in adults./...arents to take an active approach in helping their...sult with their child’s pediatrician, and for an o...
Other Medicine News:Health News:Ceramide Directs Stem Cells in Embryo 2Health News:Parasomnias are Common in Children: Study 2
Hospital Base or Surgical Center where heavy use is a requirement. Keeler, the first name in Cryo Ophthalmic Surgery has been supplying the Ophthalmic Surgeon with high performance, reliable Cryo Sy
...ilable option to correct atrial septal defects in ...ealth factors. Today's health care providers are s...defects., ,The GORE HELEX Septal Occluder is a...ivery system indicated for the transcatheter closu...
...ing and management consulting firm specializing in...y improvement, quality control, and cost reduction...g, lean enterprise, and six sigma techniques to de...t drive and sustain operational excellence. Labora...
...ing and management consulting firm specializing in...y improvement, quality control, and cost reduction...g, lean enterprise, and six sigma techniques to de...t drive and sustain operational excellence. Labora...
Medicine Products: